TY - JOUR
T1 - The role of cytokines and their antagonists in the treatment of COVID-19 patients
AU - Mohseni Afshar, Zeinab
AU - Barary, Mohammad
AU - Babazadeh, Arefeh
AU - Tavakoli Pirzaman, Ali
AU - Hosseinzadeh, Rezvan
AU - Alijanpour, Amirmasoud
AU - Allahgholipour, Amirreza
AU - Miri, Seyed Rouhollah
AU - Sio, Terence T.
AU - Sullman, Mark J.M.
AU - Carson-Chahhoud, Kristin
AU - Ebrahimpour, Soheil
N1 - Publisher Copyright:
© 2022 John Wiley & Sons Ltd.
PY - 2022
Y1 - 2022
N2 - The coronavirus disease 2019 (COVID-19) has various presentations, of which immune dysregulation or the so-called cytokine storm syndrome (COVID-CSS) is prominent. Even though cytokines are vital regulators of body immunoinflammatory responses, their exaggerated release can be harmful. This hyperinflammatory response is more commonly observed during severe COVID-19 infections, caused by the excessive release of pro-inflammatory cytokines, such as interleukin-1 (IL-1), IL-6, IL-8, tumour necrosis factor, granulocyte-macrophage colony-stimulating factor, and interferon-gamma, making their blockers and antagonists of great interest as therapeutic options in this condition. Thus, the pathophysiology of excessive cytokine secretion is outlined, and their most important blockers and antagonists are discussed, mainly focussing on tocilizumab, an interleukin-6 receptor blocker approved to treat severe COVID-19 infections.
AB - The coronavirus disease 2019 (COVID-19) has various presentations, of which immune dysregulation or the so-called cytokine storm syndrome (COVID-CSS) is prominent. Even though cytokines are vital regulators of body immunoinflammatory responses, their exaggerated release can be harmful. This hyperinflammatory response is more commonly observed during severe COVID-19 infections, caused by the excessive release of pro-inflammatory cytokines, such as interleukin-1 (IL-1), IL-6, IL-8, tumour necrosis factor, granulocyte-macrophage colony-stimulating factor, and interferon-gamma, making their blockers and antagonists of great interest as therapeutic options in this condition. Thus, the pathophysiology of excessive cytokine secretion is outlined, and their most important blockers and antagonists are discussed, mainly focussing on tocilizumab, an interleukin-6 receptor blocker approved to treat severe COVID-19 infections.
KW - COVID-19
KW - cytokine
KW - SARS-CoV-2
KW - tocilizumab
UR - http://www.scopus.com/inward/record.url?scp=85130692225&partnerID=8YFLogxK
U2 - 10.1002/rmv.2372
DO - 10.1002/rmv.2372
M3 - Review article
AN - SCOPUS:85130692225
SN - 1052-9276
JO - Reviews in Medical Virology
JF - Reviews in Medical Virology
ER -
